-+ 0.00%
-+ 0.00%
-+ 0.00%

Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target

Benzinga·10/01/2026 12:42:13
Diffusion vocale
Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.